inhibition by IgG when iMDDCs are the targets. We propose that IgG is able to efficiently inhibit HIV-1 replication in iMDDCs and should be one of the components to be induced by vaccination.
Introduction
Dendritic cells (DCs) constitute an essential component of the immune system. 1 These cells, present at trace level in all organs, 2 play a crucial role in bridging innate and acquired immune responses to pathogens. 3 Mucosal HIV-1 transmission is the major mode of infection, and immature myeloid DCs (MDCs) present at mucosal sites are among the first cells targeted by the virus. DCs play an important role in virus transmission, dissemination, persistence of HIV-1 infection and are considered as reservoirs for the virus in lymphoid tissues where they may contribute to the infection of newly recruited T lymphocytes. [3] [4] [5] [6] Different subsets of DC have been found to be infected in vivo and in vitro, [5] [6] [7] [8] [9] [10] [11] although the frequency of HIV-infected DCs is often 10-100 times lower compared to CD4 + T lymphocytes.
12
It has been reported that HIV-1 proteins, such as gp-120, Nef and Tat can each induce maturation of MDC, but maturation induced by whole HIV infectious particles is more controversial. 5, 13 Some authors have shown that plasmacytoid DCs (PDCs) can mature after in vitro infection, 14 whereas maturation of MDCs seems to occur as a bystander effect due to cytokines produced by PDCs after HIV-1 exposure. 15 On the other hand, once MDDCs are infected by HIV-1, their maturation induced by TLR4 or CD40L ligation was impaired.
13,16
Moreover, abnormal maturation induced by LPS has been measured after exposure of iMDDCs to HIV-1 gp-120. [17] [18] Recently, it has been shown that LPS-induced maturation could be prevented by addition of recombinant Vpr. 19 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
Materials and Methods

Antibodies and reagents
MAbs HLA-DR-PE (G46-6), HLA-ABC-PE (G46-2.6), CD1a-PE (HI149), CD11c-PE (HL3), CD16-PE (3G8), CD40-PE (5C3), CD80-PE (L307.4), CD83-PE (HB15e), CD86-PE (FUN-1), CD89-PE (A59), CD206-PE (19.2) and DC-SIGN-PE (DCN46) were purchased by BD-PharMingen. MAbs CD4-PC5 (13B8.2), CD8-PE (B9.11), CD14-PC5 (RMO52), CD32-PE (2E1), CD64-PC5 (22), CD45RO-ECD (UCHL1), DC-LAMP-PE (104.G4) and p24-RD1 or -FITC (KC57) were purchased by Beckman-Coulter (Roissy, France). Purified mAbs antihuman FcγRIII (3G8), FcγRII (3D3) and FcγRI (10.1) (BD-PharMingen, San Diego, CA) were used to block specific FcγR. Anti-HIV-1 human mAbs to gp-120 ( 2 fragments of these polyclonal antibodies were prepared as described. 37 Recombinant gp160 was provided by Dr R. El Habib (Aventis Pasteur).
Preparation of human iMDDCs
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were obtained by (Bordeaux) and through the NIH from Drs. S. Gartner, M. Popovic, and R. Gallo. Virus stocks were obtained as previously described 38, 39 . To eliminate the presence of bystander activation factors in virus preparation that could induce MDDC maturation, viruses were purified on sephacryl S-1000 superfin column as described. 40 Purified virus preparations were aliquoted and frozen at the concentration of 10 to 15 μg/mL of p24. For each iMDDC virus titration was performed at day 4 in conditions similar to neutralization.
Antibody neutralization assays
Neutralization was assessed by flow cytometry detection of intracellular p24 viral antigen after infection of PHA-stimulated PBMCs or iMDDCs, using experimental conditions similar to those previously described. 37 Briefly, 25 μL of purified HIV-1 (concentration ranging from 2 to 4 μg/mL of p24 depending on the strain, leading to 5% infected cells at 64 hours) were pre-incubated for 1 hour with 25 μL of mAb or polyclonal IgG or IgA purified from HIV-1 patients before the addition of 25 μL of iMDDCs at 15. 
Flow cytometry analysis
To assess the immunophenotypic profile of iMDDCs, cells were washed once with PBS plus 3% FBS and incubated for 15 min. at 4°C with antibodies. After washing, the stained cells were either fixed in 1.5% paraformaldehyde (Sigma) and/or further monitored for virus replication by intracellular p24 detection. 37,41 Cells were characterized by flow cytometry (FACScan ® , Becton Dickinson, San Jose, CA).
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Results
Immunophenotyping of iMDDCs
The phenotypic profile of human MDDCs was determined after 6 days of culture. After this period, cells had acquired the immunophenotype of iDCs (Figure 1 ). The mean percentage of MDDC expressing the costimulatory molecules CD86 and CD80 were 40 and 47% respectively, and only a very low percentage of these MDDCs was found positive for the maturation marker CD83. The loss of CD14 expression and the slow up-regulation of CD1a and FcγRII markers confirmed the differentiation of blood monocytes to DC. were added to highly purified monocytes before differentiation into iMDDCs. In the presence or in the absence of these PBLs, the cell membrane markers of iMDDCs recorded after 6 days remained almost unchanged. After this time of coculture, CD4 + T lymphocytes represented half of the total lymphocyte population and 36% of them were positive for CD69, suggesting that these blood lymphocytes were activated.
HIV-1 Infection of iMDDCs
The percentage of HIV-infected MDDCs was assessed by the detection of intracellular viral p24 Gag. Kinetics of HIV replication in iMDDCs were first determined. A few iMDDCs positive for p24 were detected at 48 hours and the percentage of p24 positive cells reached 3.5
and 18 at 64 and 96 hours respectively ( Figure 2A ). This p24 corresponds to new viral p24 proteins produced, as no intracellular p24 antigen was detected when 10 μM AZT was added together with or 24 hours after HIV-1 addition, (Figure 2A Next, the relationship between virus input and the number of HIV-infected iMDDC was assessed. Using serial dilutions of two purified HIV-1 primary isolates, we found a linear dose-response curve between the concentrations of virus inoculum ranging from 0.1 to 4 μg/mL of p24 and the percentage of infected cells ranging from 1 to 6% ( Figure 2B ). The concentration of HIV-1 allowing 5% of HIV-infected iMDDCs after 64 hours was chosen for antibody neutralization experiments to be close to the experimental conditions used for single cycle neutralization assay performed on PHA-stimulated PBMC. 41 The detection of HIV-infected cells by intracellular p24 staining used in this neutralization assay has the advantage to discriminate the infection of iMDDCs from the infection of lymphocytes. Infection of iMDDCs in the presence of autologous PBLs could thus be assessed and compared to the infection of highly purified iMDDC. In the absence of added PBLs, 5.2% of iMDDCs were infected at 64 hours whereas in the presence of 15% of autologous PBLs, 5.5% of iMDDCs (corresponding to 6.4% of the MDDC population) and 1.8% of PBLs (corresponding to 12% of the PBL population) were found infected ( Figure 2C ). After addition of neutralizing mAb 2F5 at 5 μg/mL, a strong reduction of the percentage of HIV-1 BaL -infected iMDDCs was detectable ( Figure 2C ), whereas the percentage of HIV-1 BaL -infected autologous PBLs only slightly decreased. These results showed that neutralizing mAb 2F5 was more efficient for inhibiting HIV infection of iMDDCs than blood lymphocytes.
Increased HIV neutralizing activities of anti-HIV IgG
We extended this study to various polyclonal and monoclonal Abs. 4-to 10-fold lower neutralizing concentrations of polyclonal IgG were observed on iMDDCs compared to cocultured autologous PBLs (Table 1A) . These lower neutralizing concentrations were observed whether iMDDCs were purified or cultured in the presence of 15% of autologous PBLs (Table 1A ). The HIV inhibitory activity of antibodies on autologous PBLs was comparable to that observed when PHA-stimulated PBMCs were used in a more "classical" neutralization assay.
36 When using PHA-stimulated PBMC, the HIV-1-infected cells were found to be (Table 1A) . The 90% inhibitory concentrations (IC 90 ) of five well-characterized neutralizing mAbs ranged between 1 and 5 μg/mL when iMDDCs were used, whereas their neutralizing concentrations were 10-to 50-fold higher on autologous PBLs or PHA-stimulated PBMCs (Table 1) . Moreover, when a multiple cycle HIV-1 BaL neutralization experiment was performed on highly purified iMDDCs, the concentration of mAb 2F5 resulting in 90% decrease of p24 production in the supernatant after 7 days was 1 μg/mL, a concentration similar to that determined by flow cytometry at 64 hours. On the contrary, the IC 90 of polyclonal IgA samples N°6 and 8 were similar whether iMDDCs, autologous blood lymphocytes or PHA-stimulated PBMCs were the targets of HIV-1 ( Table 1) . Polyclonal IgG or IgA purified from HIV-seronegative donors did not inhibit infection of these cells. Overall, monoclonal and polyclonal IgG exhibited more potent HIV-1 inhibitory activity when iMDDCs instead of PHA-stimulated PBMCs were used as target cells.
As HIV inhibitory activity of recombinant soluble CD4 (Table 1) 
HIV-1 inhibition by IgG is not due to iMDDC maturation
It has been previously shown that maturation of bone marrow derived mouse DCs can be induced by antigen-IgG ICs. 31 As others have indicated that HIV-1 production is lower in mature DCs than in iDCs, which may be due to a post-entry block 44 (Table 2 ). Thus, a 90% reduction of HIV-infection by antibodies was observed in the absence of induction of MDDC maturation.
Of special interest, at high concentrations of mAb 2F5 (100 μg/mL) or polyclonal IgG (650 μg/mL) a maturation signal resulting in an increased expression of CD83 (Figure 4B) and of intracellular DC-LAMP (not shown) was triggered. This maturation was observed in the presence or in the absence of infection and also with HIV-seronegative polyclonal IgG samples, demonstrating that this maturation was not related to HIV infection and was not specific to IgG directed against HIV-1. Interestingly, 650 μg/mL of polyclonal IgA sample N°8 did not induce the expression of CD83 ( Figure 4B ) or DC-LAMP (not shown) in these cells, suggesting that this mechanism of maturation is specific to FcγRs.
Participation of FcγRII in HIV-1 inhibition by anti-HIV IgG
As iMDDCs are antigen presenting cells, which express several FcγRs that can internalize antigen-IgG complexes, the involvement of the Fcγ part of the IgG in HIV-1 inhibition observed with iMDDCs was assessed. F(ab') 2 fragments of polyclonal IgG purified from HIV patients were generated and their neutralizing activities determined. As shown in Figure 5 , when purified iMDDCs were used as target cells, the neutralizing activities of the F(ab') 2 fragments were decreased compared to their corresponding whole polyclonal IgG. The neutralizing curves of these F(ab') 2 fragments were however similar to those of the F(ab' 
Participation of FcγRI in HIV-1 inhibition by anti-HIV IgG after IFN-γ treatment
It has been reported that FcγRI is expressed at the cell surface of some human DC in vivo. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From mAbs, demonstrating that the increased HIV inhibition was due to FcγRI expression on iMDDCs. Moreover, no variation in the neutralizing activity of polyclonal IgA N°8 was observed ( Figure 7D ). Overall, we describe here two mechanisms of HIV inhibition by IgG when iMDDCs are used as target cells : the first consists in the neutralization of HIV infectivity by Fab or F(ab') 2 parts of IgG (a mechanism that is common for T lymphocytes and MDDCs), and the second is based on the inhibition of HIV infection via FcγRII, or FcγRI when this latter receptor is expressed on iMDDCs.
Discussion
The aim of this study was to analyze the mechanism of HIV inhibition by antibodies when iDCs were used as target cells. For this purpose, we used DCs differentiated from human blood CD14
+ monocytes with a combination of IL-4 and GM-CSF or IL-4, GM-CSF and IFN-γ, as they exhibit immunophenotypic and functional characteristics of human blood iDCs. 47 In our culture conditions, we found that iMDDCs were infected by R5 primary isolates as recorded by intracellular p24 antigen detection. Indeed, various studies have previously reported that iDCs are susceptible to and support subsequent replication of R5
HIV-1 strains, 13,20,32,47,48 although less efficiently than CD4 + T lymphocyte. 5 We showed that addition of AZT after 24 hours of infection still completely abrogates p24 production, suggesting that HIV replication in iMDDCs was delayed compared to PHA-stimulated PBMC 41 or monocyte-derived macrophages (MDMs) 37 . It has been recently shown that HIV-1 virions were internalized in iDCs as well as in mature DCs over the first hours in the absence of viral replication. 49, 50 At that time, the virus retained could be efficiently transferred from DCs to CD4 + T lymphocytes, [48] [49] [50] [51] suggesting that virus was protected in specific DC compartments. 48 Later on, the retained HIV-1 particles were mainly destroyed in iDCs and only some may lead to productive infection. 48 Thus, DCs may transfer HIV-1 to CD4 + T lymphocytes in two distinct phases; the first one driven from an endosomal pathway (without induction of an acidic pH lysosomal degradation) to the DC-T cell synapse 49 and the second one through de novo HIV-1 production that occurs later and may be responsible for the selective transmission of R5-strains in vivo.
48
In this study, we analyzed the inhibition of R5-HIV replication by monoclonal and polyclonal IgG when iMDDCs were used as target cells. The assay used allowed us to discriminate infected iMDDCs from infected PBLs. We found that anti-HIV IgG was able to
inhibit HIV-1 replication more efficiently in iMDDCs than in PBLs, whereas no change of the neutralizing activity was observed for purified polyclonal IgA. Kinetics of IgG addition indicated that IgG inhibits an early event in HIV infection, which did not favor a mechanism of antibody-dependent cellular cytotoxicity (ADCC). NK cells could mediate ADCC but they were not detected in our MDDC preparation. Previous reports have shown that human DCs were unable to mediate ADCC, 46,52 but more recently, it has been described that a specific subset of native DC in blood from humans and mice has the ability to lyse tumor cells through efficient ADCC. 53, 54 It is well known that IgG-FcγR interaction triggers a plethora of cellular responses that include endocytosis and phagocytosis, release of inflammatory cytokines and enhancement of antigen presentation. 55, 56 Although it has been reported that ligation of FcγR by antigen-IgG
ICs could induce the maturation of mouse DCs, 31 no evidence of maturation has been observed for human iMDDCs except when FcγRIIB is blocked. 56 As maturation of DC could decrease virus production by 10-to 100-fold, probably due to a post-integration 
57,58
More recently, it has been described that FcγRIIB, which is an inhibitory FcγR, provides a feedback mechanism of DC maturation. 57 Table 2 For personal use only. on September 24, 2017. by guest www.bloodjournal.org 
